Analytical Data
-
Gene name
BAG-3
- Application
-
Alternative Names
Bcl-2-associated athanogene 3Bcl-2-binding protein Bis
-
Species
Mouse
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9JLV1
-
Expression Region
2-577aa
-
Molecular Weight
63.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BAG-3, a member of the Bcl-2-associated athanogene (BAG) family, plays a crucial role in cellular stress responses and protein homeostasis. It functions as a co-chaperone, interacting with heat shock proteins (HSPs) to modulate protein folding and degradation. Research into BAG-3 has gained momentum due to its involvement in various cellular processes, including apoptosis, autophagy, and the regulation of gene expression, making it significant in cancer biology and neurodegenerative diseases. Aberrant expression of BAG-3 has been linked to tumor progression, enhancing cancer cell survival and resistance to therapy. Moreover, its role in muscle atrophy and cardiomyopathy underscores its potential as a therapeutic target in muscle-wasting diseases. It has also emerged as a key player in the regulation of the immune response, influencing the survival of immune cells in inflammatory contexts. The complex regulatory mechanisms of BAG-3, including its post-translational modifications and interactions with other cellular pathways, highlight its potential as a biomarker and therapeutic target. Consequently, ongoing research aims to elucidate its precise mechanisms of action and therapeutic implications, paving the way for innovative treatment strategies across various diseases.
